Klinická farmakologie a farmacie – 1/2021

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2021; 35(1): 29–34 / www.klinickafarmakologie.cz 34 PŘEHLEDOVÉ ČLÁNKY Súčasný pohľad na pneumokokovú vakcináciu u dospelých: prečo nesmieme zabúdať na konjugovanú vakcínu? 24. Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, et al. Intervals between PCV13 and PPSV23 vaccines. MMWR Morb Mortal Wkly Rep 2015; 64(34): 944–947. 25. Robert Koch Institut. Empfehlungen der Ständigen Im‑ pfkommission beim Robert Koch-Institut 2020/2021. Epide‑ miologisches Bulletin 2020; 34. 20. August 2020. 26. El-Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163(3): 645–651. 27. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a po‑ pulation-based study. Clin Infect Dis 2004; 39(11): 1642–1650. 28. Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizati‑ ons for pneumonia among persons aged 65 years or older in the United States, 1988–2002. JAMA 2005; 294(21): 2712–2719. 29. Kothe H, Bauer T, Marre R, et al. Outcome of community‑ -acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32(1): 1391–1346. 30. Isturiz RE, Ramirez J, Self WH, et al. Pneumococcal epide‑ miology among us adults hospitalized for community-acqui‑ red pneumonia. Vaccine 2019; 37: 3352–3361. 31. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogeni‑ city and safety of a 13-valent pneumococcal conjugate vac‑ cine compared to a 23-valent pneumococcal polysacchari‑ de vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31(35): 3577–3584. 32. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vac‑ cine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. Vaccine 2014; 32(20): 2364–2374. 33. Shiramoto M, Hanada R, Juergens C, et al. Immunoge‑ nicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysa‑ ccharide vaccine in elderly Japanese adults. Hum Vaccines Immunother 2015; 11(9): 2198–2206. 34. van Deursen AMM, van Houten MA, Webber C, et al. Immunogenicity of the 13-valent pneumococcal conjuga‑ te vaccine in older adults with and without comorbidities in the community-acquired pneumonia immunization trial in adults (CAPiTA). Clin Infect Dis Off Publ Infect Dis Soc Am 2017; 65(5): 787–795. 35. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccha‑ ride conjugate vaccine against Pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114–1125. 36. Jefferson T, Di Pietrantonio C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010(2):CD004876. 37. Súhrn charakteristických vlastností lieku Prevenar 13. Do‑ stupné na https://www.ema.europa.eu/en/ documents/ product-information/prevenar-13-epar-product-informati‑ on_sk.pdf, (SPC Prevenar). 38. WHO, Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region.. 39. Ministerstvo zdravotnictva České republiky. Klinická sku‑ pina COVID MZ. Doporučení KS COVID MZ k provádění očko‑ vání v průběhu pandemie onemocnění COVID-19. Dátum vydania: 10.4. 2020. KS-COVID_ockovani_behem_pande‑ mie(10042020) (MZ ČR 2020). 40. Root-Bernstein R. Age and Location in Severity of CO‑ VID-19 Pathology: Do Lactoferrin and Pneumococcal Vacci‑ nation Explain Low Infant Mortality and Regional Differences? BioEssays 2020. DOI: 10.1002/bies.202000076. 41. Dražan D. Pneumokokové vakcíny. Klin Farmakol Farm 2010; 24(1): 15–18. 42. Cucchiari D, Pericàs JM, Riera J, et al. Pneumococcal su‑ perinfection in COVID-19 patients: A series of 5 cases. Med Clin (Barc) 2020; https://doi.org/10.1016/j.medcli.2020.05.022 43. Hendaus MA, Jomha FA. Covid-19 induced superimpo‑ sed bacterial infection. J Biomolecul Struct Dynamics 2020; https://doi.org/10.1080/07391102.2020.1772110. 44. Root-Bernstein R. Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococ‑ cal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death. Vaccines 2020;8:559. doi:10.3390/vacci‑ nes8040559. 45. Sultana J, Mazzaglia G, Luxi N, et al. Potential effects of vaccinations on the prevention of COVID-19: rationale, cli‑ nical evidence, risks, and public health considerations. Ex‑ pert Rev vaccines 2020. https://doi.org/10.1080/14760584. 2020.1825951.